Skip to search boxSkip to navigationSkip to main content

Effect of the baseline pulse wave velocity on short term and long term blood pressure control in primary hypertension

  • Y. Fan
    ,
  • W. Gao
    ,
  • J. Li
    ,
  • F. Fan
    ,
  • X. Qin
    ,
  • L. Liu
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Objectives: Arterial stiffness may affect antihypertensive response to antihypertensive treatment. However, sufficient clinical evidence is lacking. This longitudinal study aimed to evaluate the effect of baseline arterial stiffness measured by the brachial-ankle pulse wave velocity (baPWV) on response to short-term and long-term enalapril-based treatment in 3310 hypertensive adults from the China Stroke Primary Prevention Trial (CSPPT). Methods and results: Blood pressure (BP) measured at three months (short-term) in 2780 subjects, and the time-average on-treatment BP in 3310 subjects during a median of 4.5-year follow-ups (long-term) were analyzed in the study. After short-term antihypertensive treatment, every 1 m/s increase in baPWV denoted a 7% and 6% decreased chance of achieving systolic BP (SBP) control (odds ratio (OR), 0.93; 95% CI 0.90, 0.96; P < 0.001) and BP control (OR, 0.94; 95% CI 0.91, 0.97; P < 0.001), respectively, after adjustment for age, gender and other variables. After long-term treatment, every 1 m/s increase in baPWV posed an 7% and 6% greater risk of failing to attain SBP control (OR, 0.93; 95% CI 0.90, 0.95; P < 0.001) and BP control (OR, 0.94; 95% CI, 0.92, 0.96; P < 0.001), respectively, not regarding for DBP control after both short- and long-term treatment. Higher baseline baPWV significantly decreased SBP reduction both after three months and the median 4.5-year treatment, while increased DBP reduction after the median 4.5-year treatment. Conclusions: Elevated baseline baPWV significantly decreased BP response to short-and long-term treatment in adults with primary hypertensive. Arterial stiffness improvement may be an essential target to achieve adequate BP control.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 193-199 (7 pages)

Journal (Volume, Issue Number)

International Journal of Cardiology (Volume 317)

Publication milestones

  • Accepted/In press - 2020
  • Published - 10/15/2020

Publication status

Published - 10/15/2020

ISSN

0167-5273

Publication IDs

  • Scopus: 85085744965
  • PubMed: 32505371

Publication metrics

Metrics

Fractional count
1
Fractional count
0.09
Fractional count
10
Fractional count
0.91
Fractional count
1
Fractional count
1
SciVal
Author count
11
SciVal
Paper percentile
50
Scopus
citations

PlumX, opens in new tab

Captures
16
Citation count
4

Funding Details

All authors have completed the disclosure form and have declared the following: X. Qin reports grants from the National Science Foundation and consulting fees from AUSA Research Institute, Shenzhen AUSA. B. Wang reports grants from the National Science Foundation , Department of Science and Innovation , and Shenzhen Municipal Government , and consulting fees from AUSA Research Institute, Shenzhen AUSA. X. Xu reports grants from the Ministry of Science and Technology of the People’s Republic of China , the Major State Basic Research Development Program of China , Department of Development and Reform, Shenzhen Municipal Government , Department of Science and Innovation, Shenzhen Municipal Government, and personal fees from Shenzhen AUSA Pharmed Co Ltd.; Y. Huo reports grants from the National Major Scientific and Technological Special Project and nonfinancial support from Shenzhen AUSA . Y. Fan created original design and draft. W. Gao, J. Li, Y. Huo, X. Xu and X. Cheng provided help on study design and methodology. F. Fan and X. Wang had reviewed and edited the paper.L. Liu provided help in data curation and formal analysis. The authors report no conflicts. This research was supported by the Ministry of Science and Technology of the People's Republic of China (2012zx 09101105); and the Major State Basic Research Development Program of China (973 program, No. 2012CB517703).All authors have completed the disclosure form and have declared the following: X. Qin reports grants from the National Science Foundation and consulting fees from AUSA Research Institute, Shenzhen AUSA. B. Wang reports grants from the National Science Foundation, Department of Science and Innovation, and Shenzhen Municipal Government, and consulting fees from AUSA Research Institute, Shenzhen AUSA. X. Xu reports grants from the Ministry of Science and Technology of the People's Republic of China, the Major State Basic Research Development Program of China, Department of Development and Reform, Shenzhen Municipal Government, Department of Science and Innovation, Shenzhen Municipal Government, and personal fees from Shenzhen AUSA Pharmed Co Ltd.; Y. Huo reports grants from the National Major Scientific and Technological Special Project and nonfinancial support from Shenzhen AUSA. Y. Fan created original design and draft. W. Gao, J. Li, Y. Huo, X. Xu and X. Cheng provided help on study design and methodology. F. Fan and X. Wang had reviewed and edited the paper.L. Liu provided help in data curation and formal analysis. The authors report no conflicts. This research was supported by the Ministry of Science and Technology of the People's Republic of China ( 2012zx 09101105 ); and the Major State Basic Research Development Program of China (973 program, No. 2012CB517703 ).
FundersFunding numbers
Department of Science and Innovation
-
National Major Scientific and Technological Special Project for Significant New Drugs Development
-
Shenzhen Municipal Government
-
NSF
-
MOST
2012zx 09101105
Major State Basic Research Development Program of China
2012CB517703
National Major Science and Technology Projects of China
-